Factor VII and Fibrinogen Levels as Risk Factors for Venous Thrombosis

1994 ◽  
Vol 71 (06) ◽  
pp. 719-722 ◽  
Author(s):  
T Koster ◽  
F R Rosendaal ◽  
P H Reitsma ◽  
P A van der Velden ◽  
E Briët ◽  
...  
Keyword(s):  
Risk Factors ◽  
Deep Vein Thrombosis ◽  
Venous Thrombosis ◽  
Arterial Thrombosis ◽  
Plasma Fibrinogen ◽  
Factor Vii ◽  
Thrombotic Risk ◽  
Vein Thrombosis ◽  
Thrombosis Risk ◽  
Deep Vein

SummaryThe plasma levels of coagulation factor VII and fibrinogen are well known risk factors for arterial thrombosis. We tested the hypothesis that this association also exists for venous thrombosis. Additionally, MspI and Haelll polymorphisms in the factor VII and fibrinogen genes have recently been reported to be associated with the concentration of both proteins in the plasma. However, no conclusion could be drawn with respect to an increase or decrease in thrombosis risk. We undertook a population-based case-control study, in which 199 patients with a first, objectively confirmed episode of deep vein thrombosis, aged less than 70, and without a known malignant disorder were compared to 199 age-and sex-matched healthy controls, to evaluate the clinical importance of these reported findings.For fibrinogen we found a positive level-related association between the plasma fibrinogen level and thrombotic risk. Subjects with a plasma fibrinogen greater than 5 g/1 had an almost 4-fold increase of thrombosis risk. The frequencies of the different Haelll genotypes were out of balance only for the thrombosis patients, with a deficit of the H1H2 genotype. Possession of an H1H2 genotype was associated with a 40% reduction in thrombosis risk.For factor VII, neither the plasma level nor the MspI genotypes were related to deep vein thrombosis, although possession of a M2 allele was clearly associated with significantly lower factor VII levels. The frequencies of the Mspl-genotypes were the same for patients and control subjects and, exhibited Hardy-Weinberg equilibrium.Our results support that plasma fibrinogen, a determinant of arterial thrombosis is also a risk factor for venous thrombosis, while factor VII plasma concentration is unrelated to deep vein thrombosis, which is supported by the data from the DNA analysis of polymorphisms.

scholarly journals Predisposing Factors for Deep Venous Thrombosis in Children and Adolescents with Nephrotic Syndrome

2011 ◽  
Vol 2011 ◽  
pp. 1-5
Author(s):  
Gabriela de Toledo Passos Candelaria ◽  
Vera Maria Santoro Belangero
Keyword(s):  
Risk Factors ◽  
Nephrotic Syndrome ◽  
Deep Vein Thrombosis ◽  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
Children And Adolescents ◽  
Odds Ratio ◽  
Significant Risk ◽  
Vein Thrombosis ◽  
Deep Vein

Nephrotic syndrome (NS) is a state of hypercoagulability. In this paper, we sought to determine risk factors for the occurrence of deep vein thrombosis (DVT) in children with NS. The “with DVT” group included patients with decompensated NS and diagnosed with DVT. The “without DVT” group included the same patients, six to eighteen months prior to the episode of DVT, with decompensated NS but without DVT. Different prediction variables were analyzed. The odds ratio for the occurrence of DVT in patients with triglyceride levels ≥300 mg/dL was 3.14 (95% CI 1.14 to 8.64). For hematocrit levels ≥43% and for the presence of infection or a severe systemic event, the odds ratio was 4.37 (95% CI 1.23 to 15.53). The presence of significant risk factors for the occurrence of DVT in children with NS may serve as a warning for the occurrence of venous thrombosis.

scholarly journals Evaluation of Upper Extremity Deep Vein Thrombosis Risk Factors and Management

2018 ◽  
Vol 02 (01) ◽  
pp. 18-24
Author(s):  
Heena Sheth ◽  
Rahim Remtulla ◽  
Abuzar Moradi ◽  
Roy Smith
Keyword(s):  
Risk Factors ◽  
Deep Vein Thrombosis ◽  
Upper Extremity ◽  
Vein Thrombosis ◽  
Thrombosis Risk ◽  
Deep Vein

Gender differences in the administration of prophylaxis to prevent deep venous thrombosis

2005 ◽  
Vol 93 (02) ◽  
pp. 284-288 ◽  
Author(s):  
Nils Kucher ◽  
Victor Tapson ◽  
Rene Quiroz ◽  
Samy Mir ◽  
Ruth Morrison ◽  
...  
Keyword(s):  
Risk Factors ◽  
Gender Differences ◽  
Deep Vein Thrombosis ◽  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
Vein Thrombosis ◽  
Deep Vein ◽  
To Receive

SummaryWe investigated gender differences in the prescription of prophylaxis against deep vein thrombosis (DVT) in 2,619 patients who developed acute DVT while being hospitalized for reasons other than DVT or were diagnosed with acute DVT as outpatients but who had been hospitalized within 30 days prior to DVT diagnosis. Men were 21% more likely than women to receive prophylaxis (OR 1.21, 95% CI 1.03–1.43; p = 0.021) after adjusting for DVT risk factors, including surgery, trauma, prior DVT, age, and cancer.

Deep Vein Thrombosis in Obstetric Patients: Diagnosis and Risk Factors

1992 ◽  
Vol 67 (01) ◽  
pp. 004-007 ◽  
Author(s):  
Karin de Boer ◽  
Harry R Büller ◽  
Jan W ten Cate ◽  
Marcel Levi
Keyword(s):  
Risk Factors ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Venous Thrombosis ◽  
Diagnostic Method ◽  
Clinical Symptoms ◽  
Impedance Plethysmography ◽  
Vein Thrombosis ◽  
Deep Vein

SummaryThis study was performed to assess the prevalence of deep vein thrombosis (DVT) in consecutive obstetric patients with clinical symptoms of DVT, using impedance plethysmography (IPG) as the diagnostic method and to establish the safety of withholding anticoagulant therapy in patients with a repeatedly normal IPG. In addition, in patients with DVT the prevalence of coagulation and fibrinolytic disorders, which may explain the occurrence of venous thrombosis was investigated.Of the 77 obstetric patients with symptoms of DVT 32 (42%) had an abnormal IPG. The remaining 45 patients had a repeatedly normal IPG and showed no venous thromboembolism during a 6 months follow-up period. Twenty percent (six patients) of the patients with an abnormal IPG had a coagulation or fibrinolytic abnormality. These observations suggest that serial IPG can be used effectively in the management of obstetric patients with clinically suspected DVT and that hemostatic abnormalities are frequently found in those patients with DVT

Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis

Blood ◽  
2000 ◽  
Vol 95 (9) ◽  
pp. 2855-2859 ◽  
Author(s):  
Nico H. van Tilburg ◽  
Frits R. Rosendaal ◽  
Rogier M. Bertina
Keyword(s):  
Deep Vein Thrombosis ◽  
Venous Thrombosis ◽  
Factor V Leiden ◽  
Thrombin Activatable Fibrinolysis Inhibitor ◽  
Thrombotic Risk ◽  
Vein Thrombosis ◽  
Control Subjects ◽  
Increased Risk ◽  
Fibrinolysis Inhibitor ◽  
Deep Vein

Thrombin activatable fibrinolysis inhibitor (TAFI, or procarboxypeptidase B) is the precursor of a recently described carboxypeptidase that potently attenuates fibrinolysis. Therefore, we hypothesized that elevated plasma TAFI levels induce a hypofibrinolytic state associated with an increased risk for venous thrombosis. To evaluate this hypothesis, we developed an electroimmunoassay for TAFI antigen and used this assay to measure TAFI levels in the Leiden Thrombophilia Study, a case–control study of venous thrombosis in 474 patients with a first deep vein thrombosis and 474 age- and sex-matched control subjects. In 474 healthy control subjects, an increase of TAFI with age was observed in women but not in men. Oral contraceptive use also increased the TAFI concentration. TAFI levels above the 90th percentile of the controls (> 122 U/dL) increased the risk for thrombosis nearly 2-fold compared with TAFI levels below the 90th percentile (odds ratio, 1.7; 95% confidence interval, 1.1-2.5). Adjustment for various possible confounders did not materially affect this estimate. These results indicate that elevated TAFI levels form a mild risk factor for venous thrombosis. Such levels were found in 9% of healthy controls and in 14% of patients with a first deep vein thrombosis. Elevated TAFI levels did not enhance the thrombotic risk associated with factor V Leiden but may interact with high factor VIII levels.

Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis

2011 ◽  
Vol 105 (01) ◽  
pp. 31-39 ◽  
Author(s):  
Celine Genty ◽  
Marie-Antoinette Sevestre ◽  
Dominique Brisot ◽  
Michel Lausecker ◽  
Jean-Luc Gillet ◽  
...  
Keyword(s):  
Risk Factors ◽  
Deep Vein Thrombosis ◽  
Venous Thrombosis ◽  
Predictive Factors ◽  
Adverse Outcome ◽  
Varicose Veins ◽  
Vein Thrombosis ◽  
Increased Risk ◽  
Venous Thromboembolic ◽  
Deep Vein

SummarySuperficial venous thrombosis (SVT) prognosis is debated and its management is highly variable. It was the objective of this study to assess predictive risk factors for concurrent deep-vein thrombosis (DVT) at presentation and for three-month adverse outcome. Using data from the prospective multicentre OPTIMEV study, we analysed SVT predictive factors associated with concurrent DVT and three-month adverse outcome. Out of 788 SVT included, 227 (28.8%) exhibited a concurrent DVT at presentation. Age >75years (odds ratio [OR]=2.9 [1.5–5.9]), active cancer (OR=2.6 [1.3–5.2]), inpatient status (OR=2.3 [1.2–4.4]) and SVT on non-varicose veins (OR=1.8 [1.1–2.7]) were significantly and independently associated with an increased risk of concurrent DVT. 39.4% of SVT on non-varicose veins presented a concurrent DVT. However, varicose vein status did not influence the three-month prognosis as rates of death, symptomatic venous thromboembolic (VTE) recurrence and major bleeding were equivalent in both non-varicose and varicose SVTs (1.4% vs. 1.1%; 3.4% vs. 2.8%; 0.7% vs. 0.3%). Only male gender (OR=3.5 [1.1–11.3]) and inpatient status (OR=4.5 [1.3–15.3]) were independent predictive factors for symptomatic VTE recurrence but the number of events was low (n=15, 3.0%). Three-month numbers of deaths (n=6, 1.2%) and of major bleedings (n=2, 0.4%) were even lower, precluding any relevant interpretation. In conclusion, SVT on non-varicose veins and some classical risk factors for DVT were predictive factors for concurrent DVT at presentation. As SVT remains mostly a clinical diagnosis, these data may help selecting patients deserving an ultrasound examination or needing anticoagulation while waiting for diagnostic tests. Larger studies are needed to evaluate predictive factors for adverse outcome.

Sign in / Sign up

Export Citation Format

Share Document